BR9909677A - Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas - Google Patents
Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinasInfo
- Publication number
- BR9909677A BR9909677A BR9909677-3A BR9909677A BR9909677A BR 9909677 A BR9909677 A BR 9909677A BR 9909677 A BR9909677 A BR 9909677A BR 9909677 A BR9909677 A BR 9909677A
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- intensification
- mediated
- administration
- fusion protein
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title abstract 4
- 239000002089 prostaglandin antagonist Substances 0.000 title abstract 3
- 238000011260 co-administration Methods 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002434 immunopotentiative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
"INTENSIFICAçãO DE RESPOSTAS IMUNOLóGICAS, MEDIADAS POR PROTEìNA DE FUSãO ANTICORPO-CITOCINA, ATRAVéS DA CO-ADMINISTRAçãO COM INIBIDOR DE PROSTAGLANDINAS" Descreve-se composições e métodos para intensificar uma resposta imunológica citocida dirigida contra um tipo de célula pré-selecionada em um mamífero. Os métodos e composições baseiam-se em uma combinação de um imunoconjugado anticorpo-citocina e um inibidor de prostaglandinas. Uma vez administrado a um mamífero, o imunoconjugado induz uma resposta imunológica contra o tipo pré-selecionado de célula, como por exemplo, uma célula cancerosa, resposta essa que, como resultado da imunopotenciação por meio do inibidor de prostaglandinas, é maior do que a resposta imunológica induzida pelo imunoconjugado sozinho. Os métodos e composições são particularmente úteis para exterminar tumores sólidos ou células infectadas por vírus em um mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8216698P | 1998-04-17 | 1998-04-17 | |
| PCT/US1999/008376 WO1999053958A2 (en) | 1998-04-17 | 1999-04-16 | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9909677A true BR9909677A (pt) | 2000-12-19 |
Family
ID=22169464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9909677-3A BR9909677A (pt) | 1998-04-17 | 1999-04-16 | Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040033210A1 (pt) |
| EP (1) | EP1071469A2 (pt) |
| JP (1) | JP2002512204A (pt) |
| CN (1) | CN1305387A (pt) |
| AU (1) | AU758851B2 (pt) |
| BR (1) | BR9909677A (pt) |
| CA (1) | CA2328081A1 (pt) |
| CZ (1) | CZ20003817A3 (pt) |
| HK (1) | HK1038881A1 (pt) |
| HU (1) | HUP0101343A3 (pt) |
| MX (1) | MXPA00010151A (pt) |
| NO (1) | NO20005186L (pt) |
| PL (1) | PL343486A1 (pt) |
| RU (1) | RU2217168C2 (pt) |
| WO (1) | WO1999053958A2 (pt) |
| ZA (1) | ZA200005477B (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1037927T3 (da) | 1997-12-08 | 2004-09-06 | Emd Lexigen Res Ct Corp | Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering |
| US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
| WO1999052562A2 (en) * | 1998-04-15 | 1999-10-21 | Lexigen Pharmaceuticals Corp. | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| CZ302303B6 (cs) * | 1998-08-25 | 2011-02-16 | Merck Patent Gmbh | Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001007914A1 (en) * | 1999-07-26 | 2001-02-01 | Childrens Hospital Los Angeles Research Institute | Fenretinide increases antibody cellular toxicity |
| PL202058B1 (pl) | 1999-08-09 | 2009-05-29 | Merck Patent Gmbh | Wielofunkcyjne białko fuzyjne cytokin i przeciwciała |
| JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
| US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| DE60122286T2 (de) | 2000-02-11 | 2007-08-02 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| ES2288967T3 (es) | 2000-06-29 | 2008-02-01 | Merck Patent Gmbh | Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina. |
| BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| HUP0400284A3 (en) | 2001-05-03 | 2012-09-28 | Merck Patent Gmbh | Recombinant tumor specific antibody and use thereof |
| PL206975B1 (pl) | 2001-12-04 | 2010-10-29 | Merck Patent Gmbh | Immunocytokiny o modulowanej selektywności oraz ich zastosowanie |
| AU2003233399B2 (en) * | 2002-03-15 | 2008-03-20 | University Of North Carolina At Chapel Hill | Primitive and proximal hepatic stem cells |
| RU2366664C2 (ru) * | 2002-12-17 | 2009-09-10 | Мерк Патент Гмбх | Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2 |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| BRPI0418286A (pt) | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | proteìnas de fusão de il-7 |
| CA2551916C (en) * | 2003-12-31 | 2014-04-29 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Fc-erythropoietin fusion protein with improved pharmacokinetics |
| EP1702069A2 (en) | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| PL1706428T3 (pl) * | 2004-01-22 | 2010-02-26 | Merck Patent Gmbh | Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| AU2006332138B2 (en) | 2005-12-30 | 2012-03-22 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
| JP2009521912A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された免疫原性を有する抗ｃｄ１９抗体 |
| EA201171259A1 (ru) | 2009-04-22 | 2012-05-30 | Мерк Патент Гмбх | Антительные гибридные белки с модифицированными сайтами связывания fcrn |
| US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| SG11201810509PA (en) | 2016-06-20 | 2018-12-28 | Kymab Ltd | Anti-pd-l1 antibodies |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
| DE3812605A1 (de) * | 1988-04-15 | 1990-06-07 | Leskovar Peter Dipl Ing Dr Hab | Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes |
| JPH09506761A (ja) * | 1990-11-09 | 1997-07-08 | ステファン ディー．ギリーズ | サイトカインの免疫複合体 |
| ATE208633T1 (de) * | 1994-09-16 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| JP2002514161A (ja) * | 1996-07-02 | 2002-05-14 | バー イラン ユニバーシティー | ガンおよび他の細胞増殖性疾患の治療に有用なレチノイルオキシ（置換）アルキレンブチレート |
-
1999
- 1999-04-16 CA CA002328081A patent/CA2328081A1/en not_active Abandoned
- 1999-04-16 CZ CZ20003817A patent/CZ20003817A3/cs unknown
- 1999-04-16 EP EP99917576A patent/EP1071469A2/en not_active Ceased
- 1999-04-16 PL PL99343486A patent/PL343486A1/xx unknown
- 1999-04-16 JP JP2000544361A patent/JP2002512204A/ja active Pending
- 1999-04-16 RU RU2000125522/14A patent/RU2217168C2/ru not_active IP Right Cessation
- 1999-04-16 BR BR9909677-3A patent/BR9909677A/pt not_active IP Right Cessation
- 1999-04-16 MX MXPA00010151A patent/MXPA00010151A/es unknown
- 1999-04-16 WO PCT/US1999/008376 patent/WO1999053958A2/en not_active Ceased
- 1999-04-16 HK HK02100430.6A patent/HK1038881A1/zh unknown
- 1999-04-16 AU AU35664/99A patent/AU758851B2/en not_active Ceased
- 1999-04-16 HU HU0101343A patent/HUP0101343A3/hu unknown
- 1999-04-16 CN CN99807250A patent/CN1305387A/zh active Pending
-
2000
- 2000-10-06 ZA ZA200005477A patent/ZA200005477B/en unknown
- 2000-10-16 NO NO20005186A patent/NO20005186L/no not_active Application Discontinuation
-
2003
- 2003-05-21 US US10/442,660 patent/US20040033210A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1305387A (zh) | 2001-07-25 |
| CA2328081A1 (en) | 1999-10-28 |
| HUP0101343A3 (en) | 2003-10-28 |
| JP2002512204A (ja) | 2002-04-23 |
| ZA200005477B (en) | 2001-11-20 |
| NO20005186D0 (no) | 2000-10-16 |
| RU2217168C2 (ru) | 2003-11-27 |
| NO20005186L (no) | 2000-12-14 |
| AU3566499A (en) | 1999-11-08 |
| WO1999053958A2 (en) | 1999-10-28 |
| WO1999053958A3 (en) | 1999-12-02 |
| HK1038881A1 (zh) | 2002-04-04 |
| PL343486A1 (en) | 2001-08-27 |
| CZ20003817A3 (cs) | 2002-08-14 |
| EP1071469A2 (en) | 2001-01-31 |
| MXPA00010151A (es) | 2002-08-06 |
| HUP0101343A2 (hu) | 2001-08-28 |
| US20040033210A1 (en) | 2004-02-19 |
| AU758851B2 (en) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9909677A (pt) | Intensificação de respostas imunológicas, mediadas por proteìna de fusão anticorpo-citocina, através de co-administração com inibidor de prostaglandinas | |
| BR9909583A (pt) | Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese | |
| Ockaili et al. | HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation | |
| Li et al. | Vitamin C deficiency increases the lung pathology of influenza Virus–Infected gulo−/− mice | |
| RU2009138327A (ru) | Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака | |
| BRPI0515316A (pt) | compostos de imidazoquinolina | |
| BR0209689A (pt) | Uso de fragmento de hmg como agente anti-inflamatório | |
| ES2176502T3 (es) | Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion. | |
| BR0311939A (pt) | composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico | |
| ES2074042T3 (es) | Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores. | |
| BR0308339A (pt) | Indazóis substituìdos com uma atividade anticancerosa | |
| MX9306220A (es) | Ptp 1d: una proteina tirosina fosfatasa novedosa. | |
| EA200200097A1 (ru) | Имидазоимидазолы и триазолы в качестве противовоспалительных агентов | |
| AR022734A1 (es) | Reovirus para el tratamiento de trastornos de proliferacion celular | |
| DK1119362T3 (da) | Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion | |
| EA200000911A1 (ru) | Новые кристаллические формы антивирусного соединения бензимидазола | |
| WO2003016499A3 (en) | Combinatorial methods for inducing cancer cell death | |
| DE60023660D1 (de) | Antizymmodulatoren sowie deren verwendung | |
| BR112022001229A2 (pt) | Polipeptídeos tendo efeitos antissenescentes e usos dos mesmos | |
| EA200200808A1 (ru) | Модифицированные цитокины, предназначенные для применения в терапии рака | |
| BR112021018205A2 (pt) | Pequenos agentes bloqueadores de liberação. | |
| BR0208695A (pt) | Composições e métodos para a prevenção e tratamento de c ncer humano da próstata | |
| ATE286139T1 (de) | Replikationskompetente anti-tumor vektoren | |
| BR0107262C1 (pt) | Composição a base de monoterpenos, com efeito, quimiopreventivo e quimioterápico em neoplasias malignas de seres humanos e animais, utilização dos monoterpenos na inbição do crescimento de células tumorais e no controle de metástases de tumores primários e método especìfico de utilização da composição, com efeito, quimiopreventivo e quimioterápico em seres humanos e animais | |
| Gao et al. | N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/30 (2006.01), A61K 45/06 (2006.0 |